

REC'D 04 JUN 2003
WIPO PCT

PA 967451

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

February 26, 2003

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE UNDER 35 USC 111.

APPLICATION NUMBER: 60/364,567

FILING DATE: March 15, 2002

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

EPO - DG 1
- 105 2003
54

By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS

T. Wallace
T. WALLACE
Certifying Officer

BEST AVAILABLE COPY

3-18-2

603445 43

1574

Please type a plus sign (+) inside this box →

Approved for use through 10/31/2002 OMB 0551-0032
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
A collection of information unless it displays a valid OMB control number

Approved for use through 10/31/2002 OMB 0551-0032
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PROVISIONAL APPLICATION FOR PATENT COVER SHEET
This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

PROVISIONAL APPLICATION FOR PATENT COVER SHEET
This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.52(e)

INVENTOR(S)		
Given Name (first and middle if any)		Family Name or Surname
Ahmad Y. Thomas B.		Sheikh Borchardt
		Residence (City and either State or Foreign Country) Pleasant Valley, WI Des Plaines, IL
<input type="checkbox"/> Additional inventors are being named on the _____ separately numbered sheets attached hereto		
TITLE OF THE INVENTION (280 characters max) THE DESOLVATION/RECRYSTALLIZATION OF SOLVATES IN THE PHARMACEUTICAL INDUSTRY		
Direct all correspondence to: CORRESPONDENCE ADDRESS		
<input type="checkbox"/> Customer Number <input type="text"/>		
OR <input checked="" type="checkbox"/> Firm or Individual Name Pharmacia Corporation		
<input type="checkbox"/> Address Patent Department		
<input type="checkbox"/> Address 800 N. Lindbergh Boulevard - 04B		
<input type="checkbox"/> City St. Louis State MO ZIP 63167		
<input type="checkbox"/> Country USA Telephone 314-694-6812 Fax 314-694-9095		
ENCLOSED APPLICATION PARTS (check all that apply)		
<input checked="" type="checkbox"/> Specification Number of Pages <input type="text" value="10"/>		<input type="checkbox"/> CD(s), Number <input type="text"/>
<input type="checkbox"/> Drawing(s) Number of Sheets <input type="text"/>		<input type="checkbox"/> Other (specify) <input type="text"/>
<input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76		
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT (check one)		
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.		FILING FEE AMOUNT (\$) \$160.00
<input type="checkbox"/> A check or money order is enclosed to cover the filing fees		
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number <input type="text"/>		
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.		
The Invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.		
<input checked="" type="checkbox"/> No		
<input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are _____		
Respectfully submitted, <i>[Signature]</i>		

Respectfully submitted,

SIGNATURE

John F. T.

Date 03/15/02

TYPED or PRINTED NAME Kalim S. Fuzail

REGISTRATION NO.
(if appropriate)
Docket Number

TELEPHONE 847-581-5247

45,805

01013/1/16

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is used by the public to file (and by the PTO to process) a provisional application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, include gathering, preparing, and submitting the complete provisional application to the PTO. Time will vary depending upon the individual case. Comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the C. Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Box Provisional Application, Assistant Commissioner for Patents, Washington, D.C. 20231.

PATENT
01013/1/US

PROVISIONAL UNITED STATES PATENT APPLICATION

for

THE DESOLVATION/RECRYSTALLIZATION OF SOLVATES IN THE PHARMACEUTICAL INDUSTRY

by

Ahmad Y. Sheikh and Thomas B. Borchardt

EXPRESS MAIL MAILING LABEL

NUMBER EE8037778364S

DATE OF DEPOSIT March 15, 2002

I hereby certify that this Patent Application is being deposited with the United States Postal Service "EXPRESS MAIL POST OFFICE TO ADDRESSEE" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to:

Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

Signature Susan B. Sowle

**THE DESOLVATION/RECRYSTALLIZATION OF SOLVATES IN THE
PHARMACEUTICAL INDUSTRY**

Often, isolation of the desired crystalline form of an active pharmaceutical ingredient (API) goes through crystallizing a solvated or hydrated form of the compound. These forms are then transformed to desired solvent free forms through thermal treatment. This paper presents a theoretical framework to help develop scientifically well grounded and easy to implement strategies for robust performance during the desolvation and subsequent recrystallization of the solvated forms. The framework is comprised of Gibbs free energy temperature and composition temperature (solvent and compound) phase diagrams and also considers structural data on various polymorphs of the compounds. The utility of such diagrams in mechanistic understanding of complex and intertwined thermodynamic and kinetic events taking place during the desolvation/recrystallization process is discussed through two case studies, and simple and quick experiments to construct such diagrams for solvated forms with very different properties are identified. Translation of the theoretical framework for equipment design and process operation are also described and demonstrated for directing large scale manufacturing processes towards the isolation of thermodynamically meta-stable forms.

1. INTRODUCTION

A very significant fraction of all active pharmaceutical ingredients (API) are prepared in crystalline form for reasons related to stability and ease of handling during various stages of drug development. Often multiple crystalline forms, *i.e.*, polymorphs, solvates and hydrates exist for the API. Implications of polymorphism on properties such as dissolution rate and transport characteristics have resulted in significant emphasis on the characterization and control of the crystalline form of the API. Phase relationships between various polymorphic forms are best captured through phase diagrams.

Often, controlled isolation of the desired crystalline form of the API goes through crystallizing a solvated or hydrated form of the compound which is then transformed to the desired solvent free form through thermal treatment. Within the context of such desolvation/recrystallization processes, free energy-temperature (G-T) and composition temperature (x-T) phase diagrams are most fundamental in

developing a sound theoretical framework for the control of such processes. The G-T diagram, which is constructed by determining $2n$ properties of a polymorphic system comprised of n forms (Grunenberg *et al*, 1996), reveals two very significant practical aspects of the system *viz.*, whether the forms are monotropically or enantiotropically related and if enantiotropically related where does the transition temperature lie. When drawn in sufficient detail, this diagram also quantifies the thermodynamic driving force for the interconversions between forms as a function of temperature. One of the protocols used in this paper to construct a G-T diagram also allows determination of how the transition temperature between the solvated and non-
5 solvated form varies with solvent activity. Two-component composition-temperature (x-T) diagrams are ideally suited for understanding phase transformations through de-solvation under conditions that include presence of solvent for systems involving solvates and hydrates (Morris *et al* (2001)). Regions of stability for each of the different phases are determined in the phase space from the transition temperatures
10 determined in the G-T diagram and determination of eutectic and more importantly peritectic points. The latter is defined as the temperature at which a solvate is in equilibrium with a non-solvated form in a saturated environment. Traversing the x-T diagram along solvent content and temperature axes help identify possible pathways to isolate different non-solvated forms. The desirable trajectories of temperature and
15 solvent content can then be implemented for controlled operation of de-solvation recrystallization processes.
20

In this paper two different approaches towards the construction of G-T and x-T phase diagrams are presented. These reflect the very distinct nature of the two multi solid-form systems (referred to as compounds A and B) that were the subject of this research. The resulting framework for each of the systems is then used to identify “process related” strategies towards controlled isolation of the desired form. Results from successful implementation of these strategies at manufacturing scale are also
25 presented.

2. G-T x-T FRAMEWORK FOR COMPOUND A

30 The polymorphic system for compound A is comprised of three non-solvated forms (referred to in this work as forms I, II and III) and one ethanol solvate (IV). The API was manufactured as form I through desolvation recrystallization of form IV. Whilst simple differential scanning calorimetry (DSC) is often sufficient to obtain $2n$

parameters (for instance T_m and ΔH_{fus}), for compound A this was not possible because melting events were not observed for forms II and III due to phase conversion to form I. Furthermore, the propensity of compound A to readily solvate/hydrate in solvents made it very difficult to obtain desired thermodynamic properties from solubility 5 measurements. An alternative approach based on eutectic melting (Yu *et al*, 2000) was employed to construct a G-T diagram for forms I, II and III. The peritectic point for completion of the x-T diagram was determined through DSC and hot-stage microscopy in a sealed environment.

Eutectics were formed between three reference compounds and each of the 10 three non-solvated forms to determine heat of fusion and melting points through DSC. Table 1 summarizes the results for eutectic mixtures with forms I, II and III. The data were used to calculate free energy differences between the forms using equation 1.

$$x_{ej}(G_j - G_i)T_{ei} = \Delta Hm_{ej}(T_{ei} - T_{ej})/T_{ej} - \Delta C_{peij}[T_{ei} - T_{ej} - T_{ei}\ln(T_{ei}/T_{ej})] + RT_{ei}\{x_{ej}\ln(x_{ej}/x_{ei}) + (1 - x_{ej})\ln[(1 - x_{ej})/(1 - x_{ei})]\} \quad (1)$$

15 where x_{ej} and x_{ei} are the mole fraction of polymorphs j or i in the eutectic; $(G_j - G_i)$ is the free energy difference between polymorphs i and j; ΔHm_{ej} and ΔHm_{ei} are the enthalpy of eutectic melting; T_{ej} and T_{ei} are the temperatures of eutectic melting; ΔC_{peij} is the heat capacity change across the eutectic melt (determined from DSC baselines) and R is the ideal gas constant. The entropy difference for any given phase 20 conversion was determined from the relationship between ΔG and T , and the transition temperature was then calculated using equation 2.

$$T_t = \Delta H/\Delta S \quad (2)$$

The G-T plot (Figure 1a) showed that both forms II and III were 25 enantiotropically related to the highest melting form (form I). Transition temperatures for II to I and III to I transformations were found to be very similar. This similarity was not surprising given the narrow enthalpy gap between forms II and III. The narrow enthalpy gap also made it difficult to ascertain which of these two forms was more stable at room temperature. It was therefore predicted that any attempts to 30 selectively produce either of these forms through desolvation of IV would be very difficult.


DSC scans for form IV in a sealed pan showed an endotherm corresponding to its desolvation, immediately followed by an exotherm related to crystallization of

5 form III. These thermal events representing peritectic melting occurred over 70-110°C. This broad range was refined through hot-stage optical microscopy, which was conducted using high temperature silicon oil to mimic sealed conditions. Furthermore, a shallow temperature ramp of 1°C/min was used over the temperature range of interest. Microscopy showed that true peritectic point was approximately 72°C. The peritectic point, along with the data from the G-T diagram were used to construct the x-T diagram shown in Figure 1b.

Table 1: Eutectic melting data for the polymorphs of compound A

Crystal Form	Form I	Form II	Form III
$T_m, ^\circ\text{C}$	274-276	Phase conversion	Phase conversion
RC=phenacetin, T_m 134.5°C			
X_e	0.25	0.25	0.25
$T_e, ^\circ\text{C}$ (mean)	118.2	124.7	124.7
$\Delta H_{me}, \text{ (kJ/mole)}$	24.64	25.99	27.08
RC=benzanilide, T_m 163.0°C			
X_e	0.17	0.18	0.18
$T_e, ^\circ\text{C}$ (mean)	155.6	156.6	156.2
$\Delta H_{me}, \text{ (kJ/mole)}$	28.32	31.95	31.42
RC=salophen, T_m 187.0°C			
X_e	0.42	0.42	0.42
$T_e, ^\circ\text{C}$ (mean)	171.7	170.1	170.1
$\Delta H_{me}, \text{ (kJ/mole)}$	25.82	36.83	34.62

Figure 1: Semi-quantitative G-T and x-T diagrams for compound A



The x-T diagram identifies two routes for potential desolvation of form IV

Route ABC is an environment with inadequate solvent removal. In this environment, the composition of the system does not change rapidly as a sample on the left hand side of the solvate composition line is heated. As the temperature reaches the peritectic point, form IV transforms into a non-solvated crystal form and a saturated solution of A. The initial form that results from desolvation could be a meta-stable form or the thermodynamically stable form at that temperature. As the system is heated further, the kinetic form would transform via solution mediated transformation to the thermodynamically stable form at that temperature (form III in this case). The free energy gap between II and III is, however, very small, and consequently mixtures of II/III could also be obtained. As more and more solvent is removed from the system above the peritectic, further transformations become extremely slow in the absence of solvent mediation.

An alternate route ADE, which requires very efficient solvent removal, proceeds in such a way that most of the excess solvent (more than what defines the solvate) is removed below the peritectic point. As a consequence, when the system crosses the solvate composition line, a solid-solid mixture of form IV and non-solvated form is produced. There is no solution in this mixture as the system is below the solidus. Further removal of solvent from within the solvate below the peritectic temperature transforms more form IV through solid-solid conversion to the non-solvated form. Under these circumstances, the most likely anhydrous form to crystallize would be the kinetically favored form – form I in this case. If the temperature were to exceed the peritectic point at this stage of drying, the anhydrous form crystallized below the peritectic may not convert to form III, again because solid-solid conversion would be the mechanism, which can be extremely slow.

Whilst thermodynamic control for the crystallization of form I through form IV cannot be achieved below 164°C, a route akin to ADE offers the highest probability of success.

3. G-T x-T FRAMEWORK FOR COMPOUND B

Compound B had three non-solvated forms (referred to in this work as I, II and III) and two toluene solvates (IV and V). API was manufactured through the desolvation of form IV to I. DSC could not be used for quantitative purposes with this system because significant variations were observed in data for different lots of the same form. Most of the factors identified by Bettinetti *et al* (1999) for such variations


were prevalent in compound B. Solution calorimetry and intrinsic dissolution rate (IDR) measurements were used to determine $2n$ parameters for each of the five forms. Neat toluene was used as the solvent for solution calorimetry, while a 50/50 (v/v) toluene/heptane mixture was used in IDR experiments. The reason for using mixtures for IDR was to reduce dissolution rates to an extent that they could be measured with some accuracy. While concentration vs time data were collected for ~2 hrs, only results from the first two minutes were used to determine IDR. Table 2 lists heat of solution and IDR for all the five forms.

Table 2: Heat of solution and IDR data for compound B

Form	Heat of solution kJ/mol	IDR $\mu\text{g sec}^{-1} \text{cm}^{-2}$
I	16.62	162.00
II	24.34	78.84
III	18.31	107.46
IV	25.56	83.96
V	16.14	127.34

10 A thermodynamic model similar to that of Gu and Grant (2001) was used to construct the G-T diagram shown in Figure 2a. Usage of solution calorimetry and IDR data was extremely beneficial within this model because it allowed inclusion of forms IV and V on the diagram. Transition temperatures between solvated and non-solvated forms on this diagram are by definition the same as peritectic points on an x-T diagram. Determination of the peritectic points from the G-T diagram was particularly helpful for compound B, because low vapor pressure of toluene over the temperature range of interest made it impossible to find peritectic points using methods employed for compound A. The calculated peritectic was used to construct the x-T diagram with form IV shown in Figure 2b. While the G-T diagram unveiled many interesting relationships, the most significant observation from desolvation of form IV to I was that these two forms were essentially monotropic, with form IV being more stable until its eutectic melting in toluene. As a consequence, only structural reasons related to formation of a solvent free lattice of form IV and its collapse into an anhydrous form could lead to the isolation of form I. On the x-T diagram again two pathways *i.e.*, ABC and ADE could be identified, with the isolation of form I most likely through a pathway akin to ADE.

Figure 2: Semi-quantitative G-T and x-T diagrams for compound B



2a.

2b.


5 The following extension of the Clausius-Clapeyron equation (Chen and Grant, 1998) was used to determine sensitivity of transition temperature to toluene activity.

$$a = \exp\left(\frac{\Delta H_{tr}}{nRT_{tr}} - \frac{\Delta H_{tr}}{nRT}\right) \quad (3)$$

10 In the above equation, subscript *tr* stands for transition, ΔH for enthalpy difference between the two forms and *n* for number of moles of solvent in the solvate. Figure 3 shows the variation of the IV-II, IV-III and IV-V transition temperatures with toluene activity. The data showed that if toluene activity in the headspace were lower than the predicted value at any given temperature, the solvate would readily convert to the appropriate non-solvate. Conversely, if the toluene activity were higher than the predicted value at any given temperature, the solvate would remain stable.

Figure 3: Solvate-non solvate transition temperature vs solvent activity

15



4. PROCESS DESIGN IMPLICATIONS

For both compounds A and B, drying protocols reflective of pathway ADE

were developed and instituted. Features of these drying procedures included shallow temperature ramps and extremely efficient solvent removal through optimization of purge flowrate and strength of vacuum, especially below the peritectic point. While the latter was achieved with relative ease for compound A (peritectic temperature 5 ~72°C), for compound B (sub-ambient peritectic) almost all the excess solvent was removed through effective cake washes prior to subjecting the solids to heat. Successful implementation of these strategies resulted in significantly better control of solid form during the drying process.

5. CONCLUDING SUMMARY

10 Utility of a thermodynamic framework comprised of a G-T diagram in tandem with an x-T diagram is established for developing fundamental understanding of desolvation /recrystallization processes. Two different approaches reflective of the underlying nature of the polymorphic systems are presented for collecting the needed data to construct these diagrams. Usage of the framework to develop process designs 15 for the drying operations is discussed.

LITERATURE CITED

Bettinetti G., Mura P., Sorrenti M., Faucci M., Nergi A., 1999, *J. Pharm. Sci.*, **88**(11), 1133-1139

Chen L.R., Grant D.J.W., 1998, *Pharm. Dev. Tech.*, **3**, 487-494

20 Grunenberg A., Henck J., Siesler H.W., 1996, *Int. J. Pharm.*, **129**, 147-158

Gu C., Grant D.J.W., 2001, *J Pharm. Sci.*, **90**(9), 1277-1287

Morris K.R., Griesser U.J., Eckhardt C.J., Stowell J., 2001, *Adv. Drug Delivery Rev.*, **48**, 91-114

Yu L., Stephenson G., Mitchell C., Bunnell C., Snorek S., Bowyer J., Borchardt T., 25 Stowell J., Byrn S., 2000, *J Am. Chem. Soc.*, **122**, 585-591

WHAT IS CLAIMED IS:

1. A crystalline form of an active pharmaceutical ingredient substantially as disclosed herein.
2. A process for preparation of the crystalline form of claim 1 substantially as disclosed herein.

RECEIVED
SEARCHED
INDEXED
SERIALIZED
FILED

ABSTRACT

Utility of a thermodynamic framework comprised of a G-T diagram in tandem with an x-T diagram is established for developing fundamental understanding of desolvation /recrystallization processes. Two different approaches reflective of the 5 underlying nature of the polymorphic systems are presented for collecting the needed data to construct these diagrams. Usage of the framework to develop process designs for the drying operations is discussed.

603654-00002

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.